^
BIOMARKER:

No biomarker

News
Twitter
Trials
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 5 days
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
Ono Pharmaceuticals Press Release - 1 week
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
Ono Pharmaceuticals Press Release - 1 week
No biomarker
Urothelial Cancer
avelumab
Sensitive: A1 - Approval
ESMO.org - 1 week
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 1 week
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
Eisai Press Release - 1 week
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
Eisai Press Release - 1 week
No biomarker
Multiple Myeloma
carfilzomib + daratumumab/hyaluronidase
Sensitive: A1 - Approval
FDA - 1 week
No biomarker
HL
pembrolizumab
Sensitive: A1 - Approval
NCCN - 2 weeks
No biomarker
HL
brentuximab vedotin
Sensitive: A1 - Approval
NCCN - 2 weeks
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: A1 - Approval
BeiGene Press Release - 2 weeks
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
Gilead Press Release - 2 weeks
No biomarker
GIST
ripretinib
Sensitive: A1 - Approval
Deciphera Pharmaceuticals Press Release - 2 weeks
No biomarker
RCC
pembrolizumab
Sensitive: A1 - Approval
FDA - 2 weeks
No biomarker
Melanoma
BNT111
Sensitive: A1 - Approval
BioNTech Press Release - 2 weeks
No biomarker
HL
BEACOPP
Sensitive: A2 - Guideline
NCCN - 2 weeks
No biomarker
MDS
eltrombopag + cyclosporin A microemulsion
Sensitive: A2 - Guideline
NCCN - 2 weeks
No biomarker
CRC
arfolitixorin
Sensitive: B - Late Trials
Isofol Medical Press Release - 2 weeks
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
NHL
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
No biomarker
SCCHN
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide oral
Sensitive: A1 - Approval
No biomarker
BCC
fluorouracil topical
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
carfilzomib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
AML
glasdegib
Sensitive: A1 - Approval
No biomarker
HCC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
bortezomib + panobinostat
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
No biomarker
Lymphoma
axicabtagene ciloleucel
Resistant: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
No biomarker
CLL
rituximab + ibrutinib
Sensitive: A1 - Approval
No biomarker
SCCHN
nivolumab
Sensitive: A1 - Approval
No biomarker
AML
azacitidine oral
Sensitive: A1 - Approval
No biomarker
NSCLC
DP
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
SVd
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
No biomarker
SCCHN
TPF
Sensitive: A1 - Approval
No biomarker
AML
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
olaratumab
Sensitive: A1 - Approval
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Carcinoma
cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
No biomarker
Breast Cancer
TAC
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
pomalidomide
Sensitive: A1 - Approval
No biomarker
Burkitt Lymphoma
cyclophosphamide oral
Sensitive: A1 - Approval
No biomarker
Burkitt Lymphoma
rituximab
Sensitive: A1 - Approval
No biomarker
Adrenal Cortex Carcinoma
mitotane
Sensitive: A1 - Approval
No biomarker
Neuroendocrine Tumor
surufatinib
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
CRC
bevacizumab
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
Onbevzi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
Onbevzi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
rucaparib
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
histrelin acetate
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
cabazitaxel
Sensitive: A1 - Approval
No biomarker
Retinoblastoma
cyclophosphamide oral
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
ICP-022
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
ICP-022
Sensitive: A1 - Approval
No biomarker
CLL
ICP-022
Sensitive: A1 - Approval
No biomarker
GBM
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Neuroendocrine Tumor
sunitinib
Sensitive: A1 - Approval
No biomarker
RCC
avelumab + axitinib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive: A1 - Approval